(C) Wolf G Kroner 2009 - Bernhard KirschbaumStem Cells:
Clear away complete confusion of terms

February 2009. While many ethical questions which surround the use of stem cells have been satisfactorily answered, a number of unresolved methodological and technical issues hamper applications in the pharmaceutical industry. In the exclusive interview with B2Bioworld Bernhard Kirschbaum*, at the time Head of Global Research and Early Development for Merck Serono voices his dissatisfaction with loose scientific talk and describes his company’s approach and prospects in the field. Where are the stumbling blocks? To what extent concepts have been improved since then?

* Editor's Note: Bernd Kischbaum formally quit Merck in July 2015

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 2 pages
- Includes Merck Serono R&D pipeline May 2009

Full Company License enquire here

Back to section

Related Editorial Articles

Make or Break Drug Discovery and Biopharma of Merck Life Science

Transition Cancer Research Translation

Leroy Hood: Thinking Further about Stem Cells

Close-up: National Center for Tumor Diseases Heidelberg
An independent and non-sponsored look by B2Bioworld Editors

Merck Serono Manufacturing: We have biosimilars coming …

Bayer AG: New Stakes in Stem Cells
Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global Drug Discovery

Stem Cells: a discovery tool and a potential therapeutic modality
Jonathan Knowles, former Member of the Roche Executive Committee and Head of Group Research Leveraging different methods and technologies – clarifying the concept of personalised medicine

GSK: Stem Cell Research Now and in the Future
Patrick Vallance, today President Pharmaceuticals, R&D of GlaxoSmithKline on company strategy and the the role of cancer stem cells

Towards Drug Testing with Embryonic Stem Cells
- Towards standards for assays

The Myriad Way
Peter D Meldrum, at the time CEO of the genetics company on battles about patents, cancer chips, and competitors in commercial academia

Merck: Getting closer to biosimilars markets in Asia and Latin America